stockportfolio.pro
Stocks / LQDA vs RYTM
LQDA vs RYTM
Liquidia Corporation and Rhythm Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Liquidia Corporation (LQDA) | Rhythm Pharmaceuticals, Inc. (RYTM) | |
|---|---|---|
| Market cap | $6.2B | $5.9B |
| Revenue (latest FY) | $158.32M | $189.76M |
| Net income (latest FY) | $-68.92M | $-196.54M |
| Revenue growth (5y CAGR) | 192.5% | — |
| Net margin | -43.5% | -103.6% |
| Return on equity | -154.0% | -72.8% |
| P/E ratio | 410.7 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LQDA — free Open RYTM — freeFrequently asked questions
Which is bigger, LQDA or RYTM?
Liquidia Corporation is larger by market capitalization — $6.2B versus $5.9B.
Which grows faster, LQDA or RYTM?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.